Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments (Details)

v2.4.0.8
Financial Instruments (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Jun. 30, 2013
Contract
Jun. 30, 2012
Mar. 31, 2013
Jul. 12, 2012
Nov. 22, 2011
Financial Instruments [Abstract]          
Foreign currency transaction gains and (losses) $ 0 $ 5      
Number of open foreign exchange contracts 0        
Class of Warrant or Right [Line Items]          
Warrants outstanding (in shares) 285,454        
Non cash gains on warrants 3 1      
Note receivable - CollabRx 0        
Debt extinguishment as a consideration of acquisition 300        
Promissory note liability assumed as a purchase price of acquisition 500     500  
Investment [Line Items]          
Strategic investment 353   345 [1]    
Conversion price (in dollars per share)         $ 0.284
Nano Vibronix [Member]
         
Investment [Line Items]          
Maturity date of convertible promissory note Nov. 15, 2014        
Convertible preferred stock 3,000        
Conversion price (in dollars per share) $ 0.284        
Nano Vibronix [Member] | Convertible Promissory Note [Member]
         
Investment [Line Items]          
Strategic investment         $ 300
Interest rate on convertible promissory note (in hundredths) 10.00%        
Liability Warrants Having Exercise Price 30 [Member]
         
Class of Warrant or Right [Line Items]          
Warrants outstanding (in shares) 8,288        
Exercise price of warrants outstanding (in dollars per share) $ 30.00        
[1] Derived from the Company's audited consolidated financial statements.